Published in Prz Gastroenterol on July 01, 2015
Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol (2016) 1.39
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.83
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.35
Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology (2012) 2.64
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology (2014) 1.57
Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther (2014) 1.55
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut (2013) 1.37
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis (2011) 1.29
Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol (2014) 0.99
A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther (2003) 0.96
Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis (2015) 0.92
Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2015) 0.88
Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study. Arch Med Sci (2015) 0.82
Therapeutic and prophylactic management of bleeding from oesophageal and gastric varices - recommendations of the Working Group of the National Consultant for Gastroenterology. Prz Gastroenterol (2014) 0.80
Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Prz Gastroenterol (2014) 0.77
The importance of vitamin D in the pathology of bone metabolism in inflammatory bowel diseases. Arch Med Sci (2015) 0.77
Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group Recommendations. Prz Gastroenterol (2014) 0.76
Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn's disease naive to anti-TNF agents. Prz Gastroenterol (2015) 0.75
Disturbances in apoptosis of lamina propria lymphocytes in Crohn's disease. Arch Med Sci (2015) 0.75
Diagnostic importance of faecal markers in long-term monitoring of anti-TNF-α therapy in primary responders with Crohn's disease. Prz Gastroenterol (2015) 0.75
Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn's disease. Prz Gastroenterol (2015) 0.75